Niagen Bioscience, Inc.
NAGE · XNASCIK 1386570fmd_1HY5HK2GJ04R1YN9WGHA4NWAR3Manufacturing · Medicinal Chemicals & Botanical ProductsTemplate: Standard
Coverage: Jan 03, 2010 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 21 | 32 | 46 | 59 | 67 | 72 | 84 | 100 | 129 |
| Cost of revenue | 11 | 11 | 16 | 21 | 24 | 26 | 29 | 33 | 38 | 46 |
| Net interest income | – | – | – | – | – | (0) | 0 | 1 | – | – |
| Gross profit | 10 | 10 | 16 | 26 | 35 | 41 | 43 | 51 | 62 | 83 |
| Research and development | 3 | 4 | 5 | 4 | 3 | 4 | 5 | 5 | 6 | 6 |
| Selling, general and administrative | 11 | 22 | 44 | 53 | 52 | 65 | 57 | 51 | 48 | 63 |
| Total operating expenses | 13 | 27 | 49 | 57 | 55 | 69 | 61 | 56 | 54 | 67 |
| Operating income | (3) | (16) | (33) | (31) | (20) | (27) | (19) | (6) | 8 | 16 |
| Interest expense | 0 | 0 | 0 | 1 | 0 | 0 | – | – | – | – |
| Interest and investment income | 0 | – | – | – | – | – | – | – | 1 | 2 |
| Other non-operating income (expense) | (1) | (0) | (0) | (1) | (0) | – | – | – | – | – |
| Income before taxes | (4) | (17) | – | – | – | – | – | (5) | 9 | 18 |
| Income tax expense | 0 | 0 | – | – | – | – | – | 0 | 0 | 1 |
| Net income from continuing operations | (4) | (17) | (33) | – | – | – | – | (5) | 9 | 17 |
| Net income | (3) | (11) | (33) | (32) | (20) | (27) | (17) | (5) | 9 | 17 |